 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LBL-019 / Leads Biolabs
Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5585;
P1/2
LBL-019 is well tolerable and has demonstrated preliminary efficacy in patients with advanced malignant tumors. Clinical trial information: NCT05223231.
- LBL-019 / Leads Biolabs
LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1168;
The in-vitro and in-vivo anti-tumor activity of LBL-019 was evaluated both as a monotherapy and in combination with an anti-PD-1 antibody. The results demonstrate potent anti-tumor efficacy, supporting the advancement of LBL-019 in clinical development for the treatment of various human tumors.
- |||| LBL-019 / Leads Biolabs
Enrollment open, Monotherapy, Metastases: Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Apr 26, 2022
P1/2, N=486, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
The results demonstrate potent anti-tumor efficacy, supporting the advancement of LBL-019 in clinical development for the treatment of various human tumors. Not yet recruiting --> Recruiting
- LBL-019 / Leads Biolabs
LBL-019, a novel anti-TNFR2 antibody, shows a potent anti-tumor efficacy in a mouse MC38 model (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7048;
Not yet recruiting --> Recruiting LBL-019, a humanized anti-TNFR2 antibody, shows great anti-tumor efficacy in a mouse tumor model, likely due to the mechanisms involving enhanced proliferation of Teff, elevated IFN-γ release, and possibly killing of tumor cells and Treg. The data support further development of LBL-019 as a novel therapeutic antibody for cancer, and clinical trial is expected to launch early 2022.
- ||||| LBL-019 / Leads Biolabs
New P1/2 trial, Monotherapy, Metastases: Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors (clinicaltrials.gov) - Feb 2, 2022
P1/2, N=486, Not yet recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd